G01N 2333/70567
Nuclear receptors
Official title: Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
G01N2333/70567 (Nuclear receptors) appears on 82 US grants and 157 published applications in this corpus.
Search patents in G01N- Granted patents
- 82
- Published applications
- 157
- Assignees
- 115
- Inventors
- 392
- Latest grant
- 14 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 5 | 0 |
| 1998 | 1 | 0 |
| 1999 | 3 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 0 |
| 2002 | 5 | 6 |
| 2003 | 3 | 15 |
| 2004 | 2 | 10 |
| 2005 | 2 | 16 |
| 2006 | 5 | 10 |
| 2007 | 0 | 7 |
| 2008 | 3 | 3 |
| 2009 | 4 | 8 |
| 2010 | 3 | 8 |
| 2011 | 4 | 10 |
| 2012 | 3 | 4 |
| 2013 | 5 | 5 |
| 2014 | 2 | 4 |
| 2015 | 7 | 14 |
| 2016 | 2 | 5 |
| 2017 | 4 | 3 |
| 2018 | 5 | 2 |
| 2019 | 3 | 3 |
| 2020 | 3 | 3 |
| 2021 | 0 | 3 |
| 2022 | 2 | 3 |
| 2023 | 0 | 4 |
| 2024 | 1 | 4 |
| 2025 | 3 | 2 |
| 2026 | 0 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-ROR1 antibodies and preparation method and uses thereof14 Oct 2025US 12,441,795 B2Nanjing Immunophage Biotech Co., Ltd.
- Synthetic retinoids for use in RAR activation1 Jul 2025US 12,344,587 B2University of Durham
- Methods and compositions for targeting retinoic acid for solid tumor immunotherapy17 Jun 2025US 12,329,760 B2The Trustees of the University of Pennsylvania
- Compositions and methods for treatment of peroxisome proliferator-activated receptor gamma (PPARG) activated cancer13 Feb 2024US 11,896,678 B2Dana-Farber Cancer Institute, Inc.
- AhR-ROR-γt complex as a biomarker and therapeutic target for autoimmune disease and IL-17A-associated disease14 Jun 2022US 11,360,080 B2National Health Research Institutes
- Detecting cancer28 May 2026US 2026/0146939 A1UCL Business PLC
- Device and sensor for detection of an analyte28 May 2026US 2026/0146967 A1Reminded, Inc.
- Detecting cancer30 Apr 2026US 2026/0118368 A1UCL Business PLC
- Methods and Compositions For Targeting Retinoic Acid For Solid Tumor Immunotherapy15 Jan 2026US 2026/0014168 A1The Trustees of the University of Pennsylvania
- Synthetic retinoids for use in rar activation1 Jan 2026US 2026/0000631 A1University of Durham
Most cited
By later US patents
- Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities57US 6,218,128 B1Allergan Sales, Inc. · 2001
- Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities51US 6,942,980 B1Allergan, Inc. · 2005
- Method for modulating process mediated by farnesoid activated receptors29US 6,416,957 B1Ligand Pharmaceuticals Incorporated · 2002
- Inhibition of PPAR gamma expression by specific osteogenic oxysterols28US 8,022,052 B2The Regents of the University of California · 2011
- Farnesoid activated receptor polypeptides, and nucleic acid encoding the same25US 6,005,086 AThe Salk Institute for Biological Studies · 1999